Novo Nordisk's Weight Loss Pill Attracts 600K+ Prescriptions in 3 Months

A new weight loss pill is creating massive demand as people who avoided needle injections finally have an easier option.

Novo Nordisk (a Danish pharmaceutical company) launched its Wegovy weight loss pill in January, and it's already exploding in popularity. More than 600,000 prescriptions have been written in just three months, with over 3,000 patients starting in the first week alone.

The pill works using something called GLP-1 (a hormone that helps control appetite and blood sugar). Previously, this type of weight loss medication was only available as injections, which many people avoided because: • They're afraid of needles (affecting up to 25% of adults) • The injections cost around $1,000 per month without insurance • They were hard to access

The new pill costs between $149-299 per month depending on the dose - much cheaper than the injections. This lower price is attracting new patients who couldn't afford or didn't want the needle version.

One patient, Jane Zuckerman from Washington D.C., lost 11 pounds in her first month on the pill. She had avoided the injections due to her fear of needles but started the pill immediately when it became available.

Competition is coming: Eli Lilly (another pharmaceutical company) just got approval for their own weight loss pill called Foundayo, which could challenge Novo's early lead.

Analysts predict Wegovy pill sales could reach $2.76 billion by 2031, helping grow the overall Wegovy product line from $13.5 billion to $18.9 billion in the same period.

The pill's success shows there's huge demand for easier, more affordable weight loss medications - especially from people who were previously shut out of treatment.

This is an AI-generated summary. Read the original article at: https://www.cnbc.com/2026/04/07/novo-nordisks-wegovy-pill-launch-draws-new-wave-of-patients-to-glp-1s.html